Cargando…
The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics
PURPOSE: The aim of this study is to assess the societal burden of colorectal cancer (CRC) survivorship 2–10 years post-diagnosis in terms of (1) societal costs, and (2) quality of life/utilities, and to analyze associated patient characteristics. METHODS: This is a cross-sectional, bottom-up preval...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489543/ https://www.ncbi.nlm.nih.gov/pubmed/34510364 http://dx.doi.org/10.1007/s11764-021-01096-6 |
_version_ | 1784792905799434240 |
---|---|
author | Mulder, Frederike E. C. M. van Roekel, Eline H. Bours, Martijn J. L. Weijenberg, Matty P. Evers, Silvia M. A. A. |
author_facet | Mulder, Frederike E. C. M. van Roekel, Eline H. Bours, Martijn J. L. Weijenberg, Matty P. Evers, Silvia M. A. A. |
author_sort | Mulder, Frederike E. C. M. |
collection | PubMed |
description | PURPOSE: The aim of this study is to assess the societal burden of colorectal cancer (CRC) survivorship 2–10 years post-diagnosis in terms of (1) societal costs, and (2) quality of life/utilities, and to analyze associated patient characteristics. METHODS: This is a cross-sectional, bottom-up prevalence-based burden of disease study, conducted from a societal perspective in the Netherlands. In total, 155 CRC survivors were included. Utilities were measured by the EQ-5D-5L, using the Dutch tariffs. A cost questionnaire was developed to obtain cost information. Subgroup analyses were performed, based on patient characteristics and sensitivity analyses. RESULTS: Of all CRC survivors, 81(54%) reported no problems for mobility, 133(88%) for self-care, 98(65%) for daily activities, 59(39%) for pain/discomfort, and 112(74%) for anxiety/depression on the EQ-5D-5L. The average EQ-5D-5L utility score was 0.82 (SD = 0.2) on a scale from 0 (death) to 1 (perfect health). Significant differences in utility score were found for gender, tumor stage, number of comorbidities, and lifestyle score. The average societal costs per CRC survivor per 6 months were estimated at €971 (min = €0, max = €32,425). Significant differences in costs were found for the number of comorbidities. CONCLUSIONS: This study shows a considerable burden of CRC survivors 2–10 years after diagnosis, in comparison with survivors sooner after diagnosis and with healthy individuals in the Netherlands. IMPLICATIONS FOR CANCER SURVIVORS: Long-term care of CRC survivors should focus on improving the societal burden by identifying modifiable factors, as summarized in the WCRF/AICR lifestyle score, including body composition, physical activity, and diet. |
format | Online Article Text |
id | pubmed-9489543 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-94895432022-09-22 The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics Mulder, Frederike E. C. M. van Roekel, Eline H. Bours, Martijn J. L. Weijenberg, Matty P. Evers, Silvia M. A. A. J Cancer Surviv Article PURPOSE: The aim of this study is to assess the societal burden of colorectal cancer (CRC) survivorship 2–10 years post-diagnosis in terms of (1) societal costs, and (2) quality of life/utilities, and to analyze associated patient characteristics. METHODS: This is a cross-sectional, bottom-up prevalence-based burden of disease study, conducted from a societal perspective in the Netherlands. In total, 155 CRC survivors were included. Utilities were measured by the EQ-5D-5L, using the Dutch tariffs. A cost questionnaire was developed to obtain cost information. Subgroup analyses were performed, based on patient characteristics and sensitivity analyses. RESULTS: Of all CRC survivors, 81(54%) reported no problems for mobility, 133(88%) for self-care, 98(65%) for daily activities, 59(39%) for pain/discomfort, and 112(74%) for anxiety/depression on the EQ-5D-5L. The average EQ-5D-5L utility score was 0.82 (SD = 0.2) on a scale from 0 (death) to 1 (perfect health). Significant differences in utility score were found for gender, tumor stage, number of comorbidities, and lifestyle score. The average societal costs per CRC survivor per 6 months were estimated at €971 (min = €0, max = €32,425). Significant differences in costs were found for the number of comorbidities. CONCLUSIONS: This study shows a considerable burden of CRC survivors 2–10 years after diagnosis, in comparison with survivors sooner after diagnosis and with healthy individuals in the Netherlands. IMPLICATIONS FOR CANCER SURVIVORS: Long-term care of CRC survivors should focus on improving the societal burden by identifying modifiable factors, as summarized in the WCRF/AICR lifestyle score, including body composition, physical activity, and diet. Springer US 2021-09-11 2022 /pmc/articles/PMC9489543/ /pubmed/34510364 http://dx.doi.org/10.1007/s11764-021-01096-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Mulder, Frederike E. C. M. van Roekel, Eline H. Bours, Martijn J. L. Weijenberg, Matty P. Evers, Silvia M. A. A. The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics |
title | The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics |
title_full | The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics |
title_fullStr | The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics |
title_full_unstemmed | The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics |
title_short | The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics |
title_sort | burden of colorectal cancer survivors in the netherlands: costs, utilities, and associated patient characteristics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489543/ https://www.ncbi.nlm.nih.gov/pubmed/34510364 http://dx.doi.org/10.1007/s11764-021-01096-6 |
work_keys_str_mv | AT mulderfrederikeecm theburdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics AT vanroekelelineh theburdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics AT boursmartijnjl theburdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics AT weijenbergmattyp theburdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics AT everssilviamaa theburdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics AT mulderfrederikeecm burdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics AT vanroekelelineh burdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics AT boursmartijnjl burdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics AT weijenbergmattyp burdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics AT everssilviamaa burdenofcolorectalcancersurvivorsinthenetherlandscostsutilitiesandassociatedpatientcharacteristics |